AFJK
AFJK
Aimei Health Technology Co., LtdIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▼ |
| Q1-2025 | $0 | $413.41K ▲ | $184.66K ▼ | 0% | $0.02 ▼ | $184.66K ▼ |
| Q4-2024 | $0 | $402.02K ▲ | $444.11K ▼ | 0% | $0.05 ▼ | $444.11K ▼ |
| Q3-2024 | $0 | $200.02K | $743.51K | 0% | $0.08 | $743.51K |
What's going well?
The company is earning solid interest income ($482,171), which is keeping it profitable for now. No debt or interest expense means no financing burden.
What's concerning?
There is still no revenue, operating losses are growing, and profits rely entirely on interest income. Operating expenses are rising fast, and the business is not generating sales.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K ▼ | $43.6M ▼ | $2.38M ▲ | $41.23M ▼ |
| Q4-2024 | $28.21K ▼ | $73.81M ▲ | $1.51M ▲ | $72.31M ▲ |
| Q3-2024 | $103.56K | $72.78M | $920.79K | $71.86M |
What's financially strong about this company?
The company has a large base of investments and positive equity, meaning shareholders own much more than is owed. There are no hidden or unusual liabilities, and no goodwill or intangibles to worry about.
What are the financial risks or weaknesses?
Cash is extremely low, and all debt is due soon, creating a serious risk of running out of money. Liquidity is in crisis, and the company may need to borrow more or issue shares just to keep operating.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K ▼ | $-224.01K ▼ | $30.79M ▲ | $-30.58M ▼ | $-20.86K ▲ | $-224.01K ▼ |
| Q4-2024 | $444.11K ▼ | $-195.13K ▼ | $-277.7K ▼ | $397.48K ▲ | $-75.35K ▼ | $-195.13K ▼ |
| Q3-2024 | $743.51K | $-53.95K | $0 | $0 | $-53.95K | $-53.95K |
What's strong about this company's cash flow?
Cash burn is shrinking, with operating losses cut in half compared to last quarter. Working capital changes provided a temporary cash boost.
What are the cash flow concerns?
The company is not generating cash from its core business and must keep borrowing to survive. Cash on hand is dangerously low, and profits are not translating into real cash.
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd's financial evolution and strategic trajectory over the past five years.
AFJK currently shows strong reported profitability driven by financial income, a growing asset and equity base, and access to public capital markets. As a SPAC, it offers a potential fast-track listing and funding channel for United Hydrogen, which itself brings a wide, integrated hydrogen platform with multiple applications and a first-mover presence in parts of the Chinese market. Together, this creates a compelling strategic story if the business combination is completed and capital can be deployed effectively.
The main concerns are the absence of any operating revenue, a worsening operating loss, and a clear deterioration in liquidity and cash flow, with the company now relying more on short-term debt. The business is not self-sustaining in its current form and depends heavily on non-operating income and future capital events. There is also substantial deal risk around the United Hydrogen merger, plus sector-level risks in hydrogen: high capital needs, regulatory dependence, intense competition, and technological uncertainty.
In the near term, AFJK’s outlook is dominated by its ability to manage cash, meet obligations, and keep extending its runway until the planned merger deadline. If the United Hydrogen transaction is finalized, AFJK will transform from a financial shell into a growth-oriented, capital-intensive clean energy platform with significant opportunity but also higher operational and funding risks. The future trajectory therefore hinges on two things: closing the deal on acceptable terms and then executing in a competitive global hydrogen market where policy, technology, and capital availability can change quickly.
About Aimei Health Technology Co., Ltd
Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▼ |
| Q1-2025 | $0 | $413.41K ▲ | $184.66K ▼ | 0% | $0.02 ▼ | $184.66K ▼ |
| Q4-2024 | $0 | $402.02K ▲ | $444.11K ▼ | 0% | $0.05 ▼ | $444.11K ▼ |
| Q3-2024 | $0 | $200.02K | $743.51K | 0% | $0.08 | $743.51K |
What's going well?
The company is earning solid interest income ($482,171), which is keeping it profitable for now. No debt or interest expense means no financing burden.
What's concerning?
There is still no revenue, operating losses are growing, and profits rely entirely on interest income. Operating expenses are rising fast, and the business is not generating sales.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K ▼ | $43.6M ▼ | $2.38M ▲ | $41.23M ▼ |
| Q4-2024 | $28.21K ▼ | $73.81M ▲ | $1.51M ▲ | $72.31M ▲ |
| Q3-2024 | $103.56K | $72.78M | $920.79K | $71.86M |
What's financially strong about this company?
The company has a large base of investments and positive equity, meaning shareholders own much more than is owed. There are no hidden or unusual liabilities, and no goodwill or intangibles to worry about.
What are the financial risks or weaknesses?
Cash is extremely low, and all debt is due soon, creating a serious risk of running out of money. Liquidity is in crisis, and the company may need to borrow more or issue shares just to keep operating.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K ▼ | $-224.01K ▼ | $30.79M ▲ | $-30.58M ▼ | $-20.86K ▲ | $-224.01K ▼ |
| Q4-2024 | $444.11K ▼ | $-195.13K ▼ | $-277.7K ▼ | $397.48K ▲ | $-75.35K ▼ | $-195.13K ▼ |
| Q3-2024 | $743.51K | $-53.95K | $0 | $0 | $-53.95K | $-53.95K |
What's strong about this company's cash flow?
Cash burn is shrinking, with operating losses cut in half compared to last quarter. Working capital changes provided a temporary cash boost.
What are the cash flow concerns?
The company is not generating cash from its core business and must keep borrowing to survive. Cash on hand is dangerously low, and profits are not translating into real cash.
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd's financial evolution and strategic trajectory over the past five years.
AFJK currently shows strong reported profitability driven by financial income, a growing asset and equity base, and access to public capital markets. As a SPAC, it offers a potential fast-track listing and funding channel for United Hydrogen, which itself brings a wide, integrated hydrogen platform with multiple applications and a first-mover presence in parts of the Chinese market. Together, this creates a compelling strategic story if the business combination is completed and capital can be deployed effectively.
The main concerns are the absence of any operating revenue, a worsening operating loss, and a clear deterioration in liquidity and cash flow, with the company now relying more on short-term debt. The business is not self-sustaining in its current form and depends heavily on non-operating income and future capital events. There is also substantial deal risk around the United Hydrogen merger, plus sector-level risks in hydrogen: high capital needs, regulatory dependence, intense competition, and technological uncertainty.
In the near term, AFJK’s outlook is dominated by its ability to manage cash, meet obligations, and keep extending its runway until the planned merger deadline. If the United Hydrogen transaction is finalized, AFJK will transform from a financial shell into a growth-oriented, capital-intensive clean energy platform with significant opportunity but also higher operational and funding risks. The future trajectory therefore hinges on two things: closing the deal on acceptable terms and then executing in a competitive global hydrogen market where policy, technology, and capital availability can change quickly.

CEO
Junheng Xie
Compensation Summary
(Year )
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
KARPUS MANAGEMENT, INC.
Shares:1.03M
Value:$33.14M
FIRST TRUST CAPITAL MANAGEMENT L.P.
Shares:680K
Value:$21.97M
MIZUHO SECURITIES USA LLC
Shares:550.66K
Value:$17.79M
Summary
Showing Top 3 of 24

